The clinical utility of circulating tumour cells in patients with small cell lung cancer.

about

Small-cell lung cancer: what we know, what we need to know and the path forward.

P2860

Q47595394-377D5953-3C8B-44D2-9053-0AA879F7C1E5

P2860

The clinical utility of circulating tumour cells in patients with small cell lung cancer.

Item

http://www.wikidata.org/entity/Q41605002

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The clinical utility of circulating tumour cells in patients with small cell lung cancer.

@en

type

Item

label

The clinical utility of circulating tumour cells in patients with small cell lung cancer.

@en

prefLabel

The clinical utility of circulating tumour cells in patients with small cell lung cancer.

@en

P1476

The clinical utility of circulating tumour cells in patients with small cell lung cancer.

@en

P2093

Fabiola Fernandez-Gutierrez

http://www.w3.org/2001/XMLSchema#string

Victoria Foy

http://www.w3.org/2001/XMLSchema#string

P2860

"Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease

Interaction between circulating cancer cells and platelets: clinical implication

Specific association of human telomerase activity with immortal cells and cancer

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Cochrane diagnostic test accuracy reviews

Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

P304

409-417

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/TLCR.2017.07.05

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Caroline Dive

Corinne Faivre-Finn

Fiona Blackhall

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28904885

http://www.w3.org/2001/XMLSchema#string

P932

5583068

http://www.w3.org/2001/XMLSchema#string

The clinical utility of circulating tumour cells in patients with small cell lung cancer.

about

P2860

P2860

The clinical utility of circulating tumour cells in patients with small cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932